A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Plain-language summary

This study examined real-world data on the drug Lorlatinib in patients with metastatic ROS1-positive non-small cell lung cancer (NSCLC). Patients aged 18 and over with ROS1-positive NSCLC who received at least one dose of Lorlatinib during a defined period were included. It was a non-phase observational study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Pfizer

Intervention

Lorlatinib

Start date

7/4/2025

Estimated completion

4/14/2026

Countries

Taiwan

Related genes

Locations

• Taipei, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Patients are aged 18 years or older on index date
2. Patients have confirmed diagnosis of ROS1-positive NSCLC
3. Patients have received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023

Exclusion Criteria:

1\. Patients participated in any clinical trials using lorlatinib during the observation period.